Midlife weight gain isn’t a willpower problem. It’s a physiology shift, and the newest incretin therapies are pointing us toward the metabolic pathways that change most during perimenopause.
Midlife weight gain isn’t about eating more. It’s about a body that has quietly changed how it stores, burns, and regulates energy.
One of the most common sentences I hear in my office from women in their forties sounds something like this: I have always been able to maintain my weight, and suddenly nothing is working. They are exercising. They are eating the same foods they have always eaten. They are sleeping as well as a busy life allows. And still, the scale keeps drifting in the wrong direction.
For a long time, this experience was brushed off as simply getting older or eating too much. What we are learning is that this framing misses the bigger picture. Perimenopause is one of the most profound metabolic transitions a woman will go through in her lifetime. As ovarian hormone production declines, the effects reach far beyond the reproductive system. Appetite regulation, insulin sensitivity, body fat distribution, muscle mass, and energy expenditure all begin to shift at once.
Understanding these changes also helps explain why the newest generation of incretin therapies appears to be more effective than earlier medications. These drugs are not correcting menopause. But they do target many of the metabolic pathways that become increasingly dysregulated during this transition.
Perimenopause changes where your body stores fat
One of the hallmarks of the perimenopausal transition is a shift away from subcutaneous fat and toward visceral adipose tissue. That distinction matters. Visceral fat is not a passive storage depot. It is metabolically active tissue that surrounds the internal organs and contributes to insulin resistance, chronic inflammation, hepatic steatosis, and increased cardiometabolic risk.
This redistribution is driven in part by declining estrogen, changes in insulin sensitivity, and alterations in how the body handles energy. Many of the women I care for tell me their body shape changed long before the number on the scale did. Waistbands felt different. Clothes fit differently. The biology had shifted, even though the lifestyle had not.
Appetite is only part of the story
When semaglutide first became widely available, the public conversation focused almost entirely on appetite suppression. And that is genuinely part of how it works. GLP-1 receptor agonists increase satiety, reduce hunger, and slow gastric emptying, which naturally makes it easier to consume fewer calories. In the STEP 1 trial, semaglutide produced an average weight loss of about 15% over 68 weeks in adults with obesity (Wilding et al., 2021).
Appetite, though, is only one lever in metabolic health. For women moving through perimenopause, insulin resistance, visceral fat accumulation, and declining metabolic flexibility often become equally important drivers of weight gain. Reducing hunger alone does not fully address the underlying physiology.
Why adding GIP may matter in midlife
Tirzepatide introduced a second hormonal pathway by activating both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide, or GIP, receptor. This is meaningful because GIP does far more than influence appetite. Emerging research suggests that GIP improves adipocyte function by enhancing insulin sensitivity, promoting glucose uptake after meals, improving lipid handling, increasing adiponectin, and helping adipose tissue safely store excess nutrients rather than allowing fat to spill over into the liver or skeletal muscle (Samms & Sloop, 2025).
Those mechanisms map directly onto what happens in perimenopause. As estrogen declines, visceral adiposity tends to increase and insulin resistance often worsens. Dual agonism does not simply help women eat less. It may also improve how the body processes and stores the energy it takes in. That likely helps explain why tirzepatide consistently produces greater weight loss than GLP-1 receptor agonism alone.
Retatrutide adds another missing piece
The newest investigational therapy, retatrutide, layers glucagon receptor agonism on top of GLP-1 and GIP. At first, stimulating glucagon sounds counterintuitive, since glucagon has traditionally been thought of as the hormone that raises blood sugar. But glucagon also plays an important role in energy expenditure. Activation of glucagon receptors increases fatty acid oxidation, stimulates brown adipose tissue thermogenesis, and raises overall energy expenditure.
That last piece is especially interesting in the context of midlife. Perimenopause is associated with reductions in resting energy expenditure, progressive loss of lean muscle mass, and reduced metabolic flexibility. These medications do not reverse menopause. But targeting energy expenditure in addition to appetite may finally address more of the biology that drives midlife weight gain. In phase 2 trials, retatrutide produced mean weight loss approaching 24% after 48 weeks, with weight loss still continuing at the end of the study (Jastreboff et al., 2023).
Bigger weight loss is not the whole story
As encouraging as these therapies are, they come with important limitations that I do not want to minimize. Weight loss on GLP-1 based therapies includes some loss of lean body mass. For women entering menopause, that deserves close attention, because aging itself already increases the risk of sarcopenia and declining bone density. Losing fat improves metabolic health. Losing muscle does not.
This is why resistance training, adequate protein intake, and deliberate protection of skeletal muscle remain foundational to longevity medicine, whether or not a woman is using medication. The recent New England Journal of Medicine review also underscores another critical point: obesity is a chronic disease. Weight regain commonly occurs after treatment is discontinued, and the optimal duration of maintenance therapy is still uncertain (Rosen & Ingelfinger, 2026).
What this means for women in perimenopause
I do not think of the newest incretin therapies as simply stronger GLP-1 medications. Each generation targets additional physiologic pathways that become increasingly relevant in midlife.
- GLP-1 reduces appetite and slows gastric emptying.
- GIP appears to improve adipose tissue biology and insulin sensitivity.
- Glucagon receptor agonism may increase energy expenditure.
Together, these therapies begin to address several of the metabolic changes that accompany perimenopause, including increased hunger, worsening insulin resistance, visceral fat accumulation, and declining metabolic efficiency. They are not a replacement for the work of sleep, nutrition, resistance training, and hormone health. But they illustrate something much larger about how we should be thinking about midlife weight change.
Physiology, not willpower
Perimenopausal weight gain is not a failure of discipline. It reflects changing physiology in a body that has quietly renegotiated how it stores fat, uses fuel, and expends energy. The more clearly we understand that physiology, the better we can individualize care and support women through one of the most metabolically significant transitions of their lives.
This article is intended for educational purposes only and should not be considered medical advice. It is not a substitute for individualized evaluation, diagnosis, or treatment by a qualified healthcare professional. Healthcare decisions should be made in partnership with your clinician, taking into account your personal medical history, symptoms, and goals.
References
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple hormone receptor agonist retatrutide for obesity: A phase 2 trial. New England Journal of Medicine, 389(6), 514-526.
- Rosen, C. J., & Ingelfinger, J. R. (2026). GLP-1 receptor agonists. New England Journal of Medicine, 394(13), 1313-1324.
- Samms, R. J., & Sloop, K. W. (2025). A contemporary rationale for agonism of the GIP receptor in the treatment of obesity. Diabetes, 74, 1326-1333.
- Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
Go deeper
If you want to go deeper into how GLP-1s work and whether they might be part of your perimenopause strategy, “The GLP-1 Optimization Blueprint” walks you through the metabolic mechanisms and practical considerations these medications offer.
Lexi Yoo
Lexi Yoo, NP is a functional medicine nurse practitioner and national speaker specializing in hormones, gut health, and longevity. She helps women understand what their bodies are telling them - and turn it into a plan that actually works.
